Physician-Led Compounded Tirzepatide Evaluation for PCOS
PCOS care should account for metabolic health, symptoms, medications, and reproductive plans. Tirzepatide acts at GIP and GLP-1 receptors, but candidacy and expected response cannot be determined from mechanism alone. Highland prescribes compounded tirzepatide, which is not FDA-approved.
How Tirzepatide May Fit a PCOS Evaluation
Treatment is individualized to metabolic health, symptoms, contraindications, medications, reproductive plans, risks, and goals.
Dual Mechanism for Insulin Resistance
Tirzepatide activates both GIP and GLP-1 receptors, and may be considered only after individualized clinical review.
Body-Composition Monitoring
DEXA may be used to estimate regional fat mass and lean mass over time. Treatment cannot target one body area or guarantee a specific body-composition result.
Appetite and Tolerability Review
Appetite response and adverse effects are reviewed over time and used to individualize nutrition and medication decisions.
The Science Behind Dual GIP/GLP-1 and PCOS
PCOS is heterogeneous, and weight concerns can reflect several interacting factors. A complete evaluation considers metabolic health, symptoms, medications, sleep, nutrition, activity, and reproductive plans.
Tirzepatide acts at GIP and GLP-1 receptors. Approved-product trials do not establish the safety, effectiveness, quality, or expected outcomes of Highland's compounded formulation or predict an individual result.
For women with PCOS, this enhanced mechanism is particularly meaningful. Highland Longevity prescribes compounded tirzepatide, prepared by a state-licensed compounding pharmacy under physician supervision. Compounded tirzepatide is not FDA-approved; those approved-product trials do not establish expected outcomes for a compounded formulation or an individual patient.
- Dual GIP + GLP-1 receptor activation for enhanced insulin sensitivity
- Weight and waist trends monitored without a promised result
- DEXA-estimated regional fat and lean-mass trends when useful
- Symptoms and metabolic markers reviewed over time
Beyond Weight Loss: PCOS Symptom Improvement
Weight and metabolic changes can affect PCOS symptoms, but the response varies and fertility is not guaranteed. Follow-up may include:
- Menstrual and ovulatory patterns when relevant
- Symptoms such as acne or excess hair when relevant
- Cycle changes over time
- Clinically indicated metabolic markers
- Other symptoms or laboratory findings when clinically indicated
PCOS response varies. The plan tracks symptoms, metabolic markers, adverse effects, body-composition estimates when useful, and reproductive goals without promising a particular result.
PCOS Care Requires Individualization
"PCOS care should be individualized to symptoms, metabolic health, medications, contraindications, and reproductive plans. If a weight-loss medication is considered, we discuss approved and compounded options, limitations of the evidence, risks, and monitoring rather than promising a result."
— Dr. Josh Lindsley, DO, DABOM
Tirzepatide for PCOS FAQs
No. Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs. We do not dispense Zepbound or Mounjaro, which are brand-name tirzepatide products manufactured by Eli Lilly and Company. Compounded tirzepatide is prepared by a state-licensed compounding pharmacy under physician supervision. Compounded medications are not FDA-approved.
Tirzepatide acts at GIP and GLP-1 receptors. Whether it is appropriate for a patient with PCOS depends on metabolic health, symptoms, contraindications, medications, reproductive plans, risks, and goals. Highland prescribes compounded tirzepatide, and approved-product trials do not establish its expected outcomes.
Neither medication is approved specifically to treat PCOS. Tirzepatide acts at GIP and GLP-1 receptors, while semaglutide acts at GLP-1. Choice depends on medical history, contraindications, current medications, reproductive plans, tolerability, access, risks, and goals. Highland prescribes compounded formulations, and approved-product trials do not establish their expected outcomes.
Tirzepatide should not be used during pregnancy. Pregnancy plans, contraception, and the current product labeling must be reviewed with the prescribing clinician before treatment and before trying to conceive.
Weight-loss outcomes vary by medication, dose, duration, adherence, health conditions, and patient. Approved-product trials do not establish expected outcomes for a compounded formulation or for patients with PCOS; no amount or timeline is guaranteed. We track progress with DEXA scans to estimate changes in fat mass and lean mass over time. Highland prescribes compounded tirzepatide; those approved-product trials do not establish expected outcomes for a compounded formulation or an individual patient.
Tirzepatide is not a fertility treatment and should not be used during pregnancy. Reproductive plans and contraception should be discussed before treatment; no improvement in ovulation or fertility is guaranteed.
Compounded medications are generally not covered by health insurance. Insurance coverage typically applies only to brand-name products such as Zepbound or Mounjaro, which Highland Longevity does not dispense. We offer transparent monthly pricing for our compounded tirzepatide protocols so you know your costs upfront.
Weight regain is possible if underlying insulin resistance isn't addressed. That's why we focus on comprehensive treatment: the medication jumpstarts weight loss, while lifestyle changes and metabolic improvements help maintain results. Some patients eventually reduce or stop the medication; others maintain on low doses long-term.
Serving Fort Worth & Surrounding Communities
Our clinic is conveniently located in the Fort Worth Alliance area, just minutes from communities throughout the DFW metroplex.
Located at 4801 Golden Triangle Blvd Suite 121, Fort Worth, TX 76244
Ready for Maximum Results with PCOS?
Book a free consultation to discuss how compounded tirzepatide's dual GIP/GLP-1 mechanism can help you address insulin resistance from two angles. Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs and does not dispense Zepbound or Mounjaro.
Compounded medication disclaimer: Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs. We do not dispense Zepbound®, Mounjaro®, or any other brand-name tirzepatide product manufactured by Eli Lilly and Company.
Compounded tirzepatide is prepared by a state-licensed compounding pharmacy under the supervision of our physician. Compounded medications are not FDA-approved. They are permitted under federal law when an FDA-approved product cannot meet the patient's clinical needs, or when the FDA designates a shortage. Your physician will discuss the implications, risks, and benefits of compounded therapy at your consultation.